Learn more on this topic: Best Practices in the Management of Infectious Complications for Patients with Cancer

How do biosimilars differ from generic drugs?

James S. Lewis, PharmD, FIDSA
Oregon Health and Science University

Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.